127 related articles for article (PubMed ID: 31345340)
1. Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?
Longo V; Catino AM; Montrone M; Pesola F; Pizzutilo P; Delbene G; Gatti P; Ferrante A; Galetta D
J Thorac Oncol; 2019 Aug; 14(8):e170-e172. PubMed ID: 31345340
[No Abstract] [Full Text] [Related]
2. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
3. A Complex Renal Cyst in a Patient on Crizotinib: Case Report.
Liaw CW; Palese M; Fabrizio LD
Urology; 2019 Sep; 131():21-23. PubMed ID: 31078629
[No Abstract] [Full Text] [Related]
4. Renal Injury during Long-Term Crizotinib Therapy.
Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
6. [A case of crizotinib-associated renal cysts].
Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
[TBL] [Abstract][Full Text] [Related]
7. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
8. Alectinib shows CNS efficacy in ALK-positive NSCLC.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
[No Abstract] [Full Text] [Related]
9. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.
Kopelevich A; Holzman SA; La J; Lai HA; Torno L; Stephany HA
Urology; 2021 Mar; 149():222-224. PubMed ID: 32882306
[TBL] [Abstract][Full Text] [Related]
11. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
12. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
13. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter defibrillator for alectinib induced ventricular fibrillation.
Mandal AKJ; Stokes SA; Missouris CG
Clin Toxicol (Phila); 2020 Jul; 58(7):781-784. PubMed ID: 31631703
[No Abstract] [Full Text] [Related]
15. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
16. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
17. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.
Klempner SJ; Aubin G; Dash A; Ou SH
Oncologist; 2014 Sep; 19(9):1008-10. PubMed ID: 25096999
[TBL] [Abstract][Full Text] [Related]
19. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
20. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]